Abstract
Analysis of the spread and frequency of SARS-CoV-2 D614G in the United Kingdom suggests a selective advantage for this strain that is associated with higher viral loads in younger patients but not higher COVID-19 clinical severity or mortality.
| Original language | English |
|---|---|
| Pages (from-to) | 64-75.e11 |
| Journal | Cell |
| Volume | 184 |
| Issue number | 1 |
| Early online date | 18 Nov 2020 |
| DOIs | |
| Publication status | Published - 7 Jan 2021 |
Keywords
- COVID-19
- epidemiology
- evolution
- founder effect
- SARS-CoV-2
- spike
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. / Colquhoun, Rachel M.; da Silva Filipe, Ana; Shepherd, James; Pascall, David J.; Shah, Rajiv; Jesudason, Natasha; Li, Kathy; Jarrett, Ruth; Pacchiarini, Nicole; Bull, Matthew; Geidelberg, Lily; Siveroni, Igor; COG-UK Consortium; Goodfellow, Ian; Loman, Nicholas J.; Pybus, Oliver G.; Robertson, David L.; Thomson, Emma C.; Rambaut, Andrew; Connor, Thomas R.
In: Cell, Vol. 184, No. 1, 07.01.2021, p. 64-75.e11.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity
AU - Volz, Erik
AU - Hill, Verity
AU - McCrone, John T.
AU - Price, Anna
AU - Jorgensen, David
AU - O'Toole, Áine
AU - Southgate, Joel
AU - Johnson, Robert
AU - Jackson, Ben
AU - Nascimento, Fabricia F.
AU - Rey, Sara M.
AU - Nicholls, Samuel M.
AU - Colquhoun, Rachel M.
AU - da Silva Filipe, Ana
AU - Shepherd, James
AU - Pascall, David J.
AU - Shah, Rajiv
AU - Jesudason, Natasha
AU - Li, Kathy
AU - Jarrett, Ruth
AU - Pacchiarini, Nicole
AU - Bull, Matthew
AU - Geidelberg, Lily
AU - Siveroni, Igor
AU - COG-UK Consortium
AU - Goodfellow, Ian
AU - Loman, Nicholas J.
AU - Pybus, Oliver G.
AU - Robertson, David L.
AU - Thomson, Emma C.
AU - Rambaut, Andrew
AU - Connor, Thomas R.
AU - Davidson, Rosemary
N1 - Funding Information: We thank all partners and contributors to the COG-UK consortium who are listed at https://www.cogconsortium.uk/about/ . We also acknowledge the important work of SARS-CoV-2 genome data producers globally contributing sequence data to the GISAID database and particularly acknowledge the groups who have generated data used by this project, listed in Table S4 . E.V. acknowledges the MRC Centre for Global Infectious Disease Analysis ( MR/R015600/1 ). R. Johnson and E.V. acknowledge funding from the European Commission (CoroNAb 101003653 ). V.H. was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant no. BB/M010996/1 ). J.T.M., R.M.C., N.J.L., and A.R. acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z – ARTIC network). A.R. is supported by the European Research Council (grant agreement no. 725422 – ReservoirDOCS). D.L.R., A.d.S.F., and E.C.T. are supported by the MRC ( MC_UU_1201412 ). J. Southgate was supported by the BBSRC -funded South West Biosciences Doctoral Training Partnership (training grant reference BB/M009122/1 ). T.R.C. and N.J.L. acknowledge support from the MRC , which funded computational resources used by the project (grant reference MR/L015080/1 ). T.R.C. acknowledges funding as part of the BBSRC Institute Strategic Programme Microbes in the Food Chain ( BB/R012504/1 ) and its constituent projects ( BBS/E/F/000PR10348 and BBS/E/F/000PR10352 ). A.P. and T.R.C. acknowledge support from Supercomputing Wales , which is partially funded by the European Regional Development Fund (ERDF) via Welsh Government . The project was also supported by specific funding from Welsh Government , which provided funds for the sequencing and analysis of a subset of the Welsh samples used in this study, via Genomics Partnership Wales. Funding Information: We thank all partners and contributors to the COG-UK consortium who are listed at https://www.cogconsortium.uk/about/. We also acknowledge the important work of SARS-CoV-2 genome data producers globally contributing sequence data to the GISAID database and particularly acknowledge the groups who have generated data used by this project, listed in Table S4. E.V. acknowledges the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1). R. Johnson and E.V. acknowledge funding from the European Commission (CoroNAb 101003653). V.H. was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant no. BB/M010996/1). J.T.M. R.M.C. N.J.L. and A.R. acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z ? ARTIC network). A.R. is supported by the European Research Council (grant agreement no. 725422 ? ReservoirDOCS). D.L.R. A.d.S.F. and E.C.T. are supported by the MRC (MC_UU_1201412). J. Southgate was supported by the BBSRC-funded South West Biosciences Doctoral Training Partnership (training grant reference BB/M009122/1). T.R.C. and N.J.L. acknowledge support from the MRC, which funded computational resources used by the project (grant reference MR/L015080/1). T.R.C. acknowledges funding as part of the BBSRC Institute Strategic Programme Microbes in the Food Chain (BB/R012504/1) and its constituent projects (BBS/E/F/000PR10348 and BBS/E/F/000PR10352). A.P. and T.R.C. acknowledge support from Supercomputing Wales, which is partially funded by the European Regional Development Fund (ERDF) via Welsh Government. The project was also supported by specific funding from Welsh Government, which provided funds for the sequencing and analysis of a subset of the Welsh samples used in this study, via Genomics Partnership Wales. Conceptualization, E.V. N.J.L. A.R. and T.R.C.; Data Generation, S.M.R. J. Shepherd, R.S. K.L. N.P. M.B. D.L.R. E.C.T. and COG-UK; Methodology, E.V. J. Southgate, D.J.P. R.S. K.L. R. Jarrett, E.C.T. and A.R.; Software, E.V. S.M.N. M.B. I.S. and A.R.; Analysis, E.V. V.H. J.T.M. A.P. A.O. J. Southgate. S.M.R. J. Shepherd. D.J.P. L.G. O.G.P. E.C.T. A.R. and T.R.C.; Writing ? Original Draft, E.V. V.H. J.T.M. A.P. F.F.N. A.R. and T.R.C.; Writing ? Review & Editing, D.J. B.J. F.F.N. A.d.S.F. N.J. L.G. I.G. N.J.L. O.G.P. D.L.R. and E.C.T.; Visualization, E.V. V.H. A.P. D.J. A.O. R. Johnson, J. Shepherd, and A.R.; Supervision, E.V. N.J.L. D.L.R. E.C.T. A.R. and T.R.C.; Funding Acquisition, E.V. N.J.L. E.C.T. A.R. and T.R.C. The authors declare no competing interests. Publisher Copyright: © 2020 The Author(s)
PY - 2021/1/7
Y1 - 2021/1/7
N2 - Analysis of the spread and frequency of SARS-CoV-2 D614G in the United Kingdom suggests a selective advantage for this strain that is associated with higher viral loads in younger patients but not higher COVID-19 clinical severity or mortality.
AB - Analysis of the spread and frequency of SARS-CoV-2 D614G in the United Kingdom suggests a selective advantage for this strain that is associated with higher viral loads in younger patients but not higher COVID-19 clinical severity or mortality.
KW - COVID-19
KW - epidemiology
KW - evolution
KW - founder effect
KW - SARS-CoV-2
KW - spike
UR - http://www.scopus.com/inward/record.url?scp=85098925617&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2020.11.020
DO - 10.1016/j.cell.2020.11.020
M3 - Article
AN - SCOPUS:85098925617
VL - 184
SP - 64-75.e11
JO - Cell
JF - Cell
SN - 0092-8674
IS - 1
ER -